💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Biperiden

CHEMBL1101 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
311.5 g/mol
LogP
4.3
Phase
4

An anticholinergic medication used to treat symptoms of Parkinson's disease and drug-induced movement disorders such as akathisia and dystonia. It reduces tremor, rigidity, and muscle spasms by blocking muscarinic receptors in the brain. Common side effects include dry mouth, constipation, and urinary retention.

आणविक भार

311.5000 g/mol

LogP

4.30

TPSA

23.50 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

जनरलाइज़्ड एंग्ज़ाइटी डिसऑर्डर मिर्गी (एपिलेप्सी) सिज़ोफ्रेनिया

क्रिया का तंत्र

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2

                

                

                
                

                    
InChI

                    
InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2

                

                

                

                    
                    

                        
Molecular Formula

                        
C21H29NO

                    

                    
                    

                        
HBD / HBA

                        
1 / 2

                    

                    
                    

                        
घूर्णनीय बंधन

                        
5

                    

                    
                    
                    

                        
भारी परमाणु

                        
23

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
An anticholinergic medication used to treat symptoms of Parkinson's disease and drug-induced movement disorders such as akathisia and dystonia. It reduces tremor, rigidity, and muscle spasms by blocking muscarinic receptors in the brain. Common side effects include dry mouth, constipation, and urinary retention.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Biperiden is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1101.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 2381.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.